Medicine, Health & Food

Medicine, Health & Food

Dual Antiplatelet Therapy in Cardiology: Novel Guidelines

Pages: 9  ,  Volume: 29  ,  Issue: 2 , May   2019
Received: 28 May 2019  ,  Published: 17 June 2019
Views: 33  ,  Download: 9

Authors

# Author Name
1 Giuseppe Cocco
2 Philpp Amiet

Abstract

Dual antiplatelets therapy is a cornerstone treatment in patients with coronary artery disease at risk for ischemic events. The potent and long dual antiplatelets therapy reduces risk of ischemic coronary events but is associated with an increased risk of bleeding complications and a consequent higher morbidity and mortality. Because of the huge amount of new scientific data on DAPT the European Society of Cardiology and the European Association of Cardio-Thoracic Surgery have recently updated the guidelines. This short review gives the 'state of the art' of this important therapy.

Keywords

  • Dual antiplatelet therapy
  • References

    1.

    Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

    N Engl J Med 1996;334/17:1084–1089. doi: 10.1056/NEJM199604253341702.

    2.

    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes.

    N Engl J Med 2007;357/20:2001–2015. doi: 10.1056/NEJMoa0706482.

    3.

    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H et al. PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

    N Engl J Med 2009;361/11:1045–1057. doi:10.1056/NEJMoa0904327.

    4.

    Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction.

    N Engl J Med 2015;372/19:1791–1800. doi: 10.1056/NEJMoa1500857.

    5.

    Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE et al. DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

    N Engl J Med 2014;371/23:2155–2166. doi: 10.1056/NEJMoa1409312.

    6.

    Navarese EP, Andreotti F, Schulze V, Ko?odziejczak M, Buffon A et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ 2015;350:h1618. doi: 10.1136/bmj.h1618.

    7.

    Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? Eur Heart J 2015;36/20:1219–1222.

    doi: 10.1093/eurheartj/ehv053.

    8.

    Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.

    Eur Heart J 2017;38/11:804–810. doi: 10.1093/eurheartj/ehx085.

    9.

    Costa F, Ariotti S, Valgimigli M, Kolh P, Windecker S. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization: Fifty Years of Revascularization: Where Are We and Where Are We Heading?

    J Cardiovasc Transl Res 2015;8/4:211–220. doi: 10.1007/s12265-015-9632-6.

    10.

    Collet JP, Roffi M, Byrne RA, Costa F, Valgimigli M et al. Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC); ESC Scientific Document Group; Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC). Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease.

    Eur Heart J 2018;39/3:e1–33. doi: 10.1093/eurheartj/ehx503.

    11.

    Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

    Eur Heart J 2018;39/3:213–260. doi: 10.1093/eurheartj/ehx419.

    12.

    Costa F, Valgimigli M. Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let’s Re-Evaluate Our Priorities. J Am Coll Cardiol. 2015;66/10:1203–1204.

    doi: 10.1016/jacc.2015.05.080.

    13.

    Costa F, Valgimigli M. Novel directions for the management of dual antiplatelet therapy in patients with coronary artery disease. CardioVasc Medicine 2019;22:w0224:31-35.

    doi: 10.4414/cvm.2019.02024.

    14.

    Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ et al. DAPT Study Investigators. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol 2015;65/20:2211–2221.

    doi: 10.1016/j.jacc.2015.03.003.

    15.

    Costa F, Vranckx P, Leonardi S, Moscarella E, Ando G et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.

    Eur Heart J 2015;36/20:1242–1251. doi: 10.1093/eurheartj/ehv038.

    16.

    Crimi G, Leonardi S, Costa F, Ariotti S, Tebaldi M et al. Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. Catheter Cardiovasc Interv 2015;86/1:E19–27. doi. 10.1002/ccd.25822.

    17.

    Adamo M, Costa F, Vranckx P, Leonardi S, Navarese EP et al. Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. Int J Cardiol 2015;190:242–245. doi: 10.1016/j.ijcard.2015.04.159.

    18.

    Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction.

    N Engl J Med 2015;372/19:1791–1800. doi: 10.1056/NEJMoa1500857.

    19.

    Magnani G, Storey RF, Steg G, Bhatt DL, Cohen M et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J 2016;37/4:400–408. doi: 10.1093/eurheartj/ehv482.

    20.

    Costa F, Adamo M, Ariotti S, Navarese EP, Biondi-Zoccai G et al. Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis.

    Int J Cardiol 2015;201:179–181. doi: 10.1016/j.ijcard.2015.08.058.

    21.

    Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG et al. DAPT Study Investigators. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.

    JACC Cardiovasc Interv 2016;9/2:138–147. doi: 10.1016/j.jcin.2015.10.001.

    22.

    Valgimigli M, Costa F, Byrne R, Haude M, Baumbach A, Windecker S. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey.

    EuroIntervention 2015;11/1:68–74. doi: 10.4244/EIJV11I1A11.

    23.

    Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F et al. Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. J Am Coll Cardiol 2016;68(17):1851–64.

    doi: 10.1016/j.jacc.2016.07.760.

    24.

    Costa F, Adamo M, Ariotti S, Ferrante G, Navarese EP et al. Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. EuroIntervention 2016;11/11:e1222–1230. doi: 10.4244/EIJY15M08_04.

    25.

    Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrié D et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.

    Lancet 2016;388/10059:2479–2491. doi: 10.1016/S0140-6736(16)32050-5.

    26.

    Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C et al. ZEUS Investigators. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.

    JACC Cardiovasc Interv 2016;9/5:426–436. doi: 10.1016/j.jcin.2015.11.015.

    27.

    Ariotti S, Costa F, Valgimigli M. Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk: navigating between limited evidence and clinical concerns. Curr Opin Cardiol 2015;30/4:325–332. doi: 10.1097/HCO.0000000000000185.

    28.

    Armstrong EJ, Sab S, Singh GD, Lim W, Yeo KK et al. Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry.

    JACC Cardiovasc Interv 2014;7/10:1105–1113. doi: 10.1016/j.jcin.2014.05.017.

    29.

    Mehran R, Baber U, Steg PG, Ariti C, Weisz G et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382(9906):1714–22. doi:10.1016/S0140-6736(13)61720-1.

    30.

    Valgimigli M, Garcia H, Vrijens B, Vranckx P, McFadden EP et al. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC).

    Eur Heart J 2018. [Epub ahead of print] doi: 10.1093/eurheartj/ehy377.

    31.

    Costa F, Tijssen JG, Ariotti S, Giatti S, Moscarella E et al. Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy.

    J Am Heart Assoc. 2015;4/12:e002524. doi: 10.1161/JAHA.115.002524

    32.

    Andó G, Costa F. Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach? Postepy Kardiol Interwencyjnej. 2015;11/3:170–173.

    doi: 10.5114/pwki.2015.54007.

    33.

    Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH et al. DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016;315/16:1735–1749.

    doi: 10.1001/jama.2016.3775.

    34.

    Costa F, van Klaveren D, James S, Heg D, Räber L, et al. PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials Lancet 2017;389/10073:1025–1034.

    doi: 10.1016/S0140-6736(17)30397-5.

    35.

    Sawaya FJ, Morice MC, Spaziano M, Mehran R, Didier R et al.Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials.

    Catheter Cardiovasc Interv 2017;89/2:178–189. doi: 10.1002/ccd.26653.

     

    36.

    Crimi G, Leonardi S, Costa F, Ariotti S, Tebaldi M et al. Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. Catheter Cardiovasc Interv 2015;86/1:E19–27. doi:.10.1002/ccd.25822.

    37.

    Crimi G, Leonardi S, Costa F, Adamo M, Ariotti S, Valgimigli M. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. Int J Cardiol 2016;212:110–117. doi: 10.1016/j.ijcard.2016.03.033.

    38.

    Gargiulo G, Santucci A, Piccolo R, Franzone A, Ariotti S et al. Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. Catheter Cardiovasc Interv 2017;90/4:E73–84. doi: 10.1002/ccd.26921.

    39.

    Gargiulo G, Windecker S, da Costa BR, Feres F, Hong MK et al. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.

    BMJ 2016;355:i5483. doi: doi.org/10.1136/bmj.i5483.

    40.

    Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M et al.Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54.

    J Am Coll Cardiol 2016;67/23:2732–40. doi: 10.1016/j.jacc.2016.03.529.

    41.

    Meredith IT, Tanguay JF, Kereiakes DJ, Cutlip DE, Yeh RW, et al. DAPT Study Investigators. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016;133(18):1772–82.

    doi:. http://dx.doi.org/10.1161/CIRCULATIONAHA.115.016783.

    42.

    Adamo M, Costa F, Vranckx P, Leonardi S, Navaraese EP et al. Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration?. Insights from the PRODIGY trials. Int. J Cardiol 2015;190:242-5. doi: 10.1016/j,jicard.2015.04.159.

    43.

    Widmann J, Filipovic M. Perioperative Medikation bei nicht kardialen Operationen. Richtiger Umgang mit medikamentöser Dauertherapie. info@herz+gefäss 2019;9/2:5-8.

    44.

    Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M  et al. ATACAS Investigators of the ANZCA Clinical Trials Network. Stopping vs. Continuing Aspirin before Coronary Artery Surgery.

    N Engl J Med. 2016;374/8:728–737. doi: 10.1056/NEJMoa1507688.

    45.

    Egholm G, Kristensen SD, Thim T, Olesen KK, Madsen M, Jensen SE et al. Risk Associated With Surgery Within 12 Months After Coronary Drug-Eluting Stent Implantation.

    J Am Coll Cardiol. 2016;68/24:2622–2632. doi: 10.1016/j.jacc.2016.09.967.